Evidence database

Best practice portal main page

Take-home naloxone (THN) economic evaluation

Summary of the evidence

Rating
  • Beneficial

Community distribution of naloxone was the focus of a systematic reviews of economic evaluations (Cherrier et al., 2022, 10 studies, one cost-effectiveness analysis, eight cost-utility analyses, and one cost-benefit analysis) and results showed that:

  • all studies concluded that community distribution of naloxone was cost effective, with an incremental cost-utility ratio range of $US111-58,738 (year 2020 values) per quality-adjusted life-year gained.

Details

Note: this evidence summary is only valid for the outcomes, target groups, settings and substances/patterns of use described below.

Name of response option
  • Naloxone administration
Area(s)
  • Harm reduction
Specific substance or pattern of use
  • opioids
Target group(s) or setting(s)
  • PWID – people who inject drugs

References

Explore all resources in the Best practice portal

 

Miniguides

A one-stop-shop for anyone planning or delivering health and social responses.

 

Implementation

Implementation inventories including Xchange, Healthy Nightlife Toolbox, EUPC and EIB

 

Evidence

All of the latest research and evidence on drug-related interventions.

 

Standards

Standards and guidelines for drug-related interventions, aimed at improving their quality.

About the Best practice portal

Collaborations and partnerships in best practice

Logo of the Cochrane Collaboration
Logo of the Campbell Collaboration
Grade logo
WHO logo
Top